中新社合肥2月12日电 (记者赵强)安徽省商务厅副厅长、省自贸办常务副主任后其洁12日披露，中国(安 徽)自由贸易试验区(下称"安徽自贸试验区")支持符合条件的港澳台医生取得医师资格证书后，在该自贸 试验区短期执业。 此次《试点举措》凸显四大特色，突出全链条改革、制度型开放、市场化导向和高质量发展。其中，在 制度型开放方面，除支持港澳台医生短期执业外，还吸引境外高端医药人才入驻，汇聚全球创新资源。 市场化导向下，针对企业诉求推出"双白名单"等制度，优化监管服务。 后其洁表示，安徽将跟踪政策落地，优化相关举措并复制推广经验，同时健全风险管控机制，严守伦 理、生物安全等底线，确保生物医药创新发展行稳致远。(完) （文章来源：中国新闻网） 当天，《关于支持中国(安徽)自由贸易试验区合肥片区生物医药产业链关键环节集成创新试点举措》(下 称《试点举措》)政策解读新闻发布会在合肥举行。 后其洁在会上介绍，《试点举措》围绕支持合肥片区生物医药产业研发、生产、审评、应用等关键环 节，从4方面提出20项具体举措。这是安徽自贸试验区设立以来首个产业链集成创新措施。 据悉，《试点举措》构建起"研发—生产—审评—应用"全链条支持体系 ...

Core Insights - The fifth Shenzhen Biopharmaceutical Innovation Conference was successfully held, focusing on innovation and international development in the biopharmaceutical industry, aiming to promote high-quality integration and global cooperation in the Guangdong-Hong Kong-Macao Greater Bay Area [1] Group 1: Conference Overview - The conference adopted a dual-mode format of offline main venue and online live streaming, attracting nearly 3,500 participants, including industry experts, corporate representatives, and investors [1] - Keynote speeches and discussions centered around "new opportunities for biopharmaceutical innovation and going global," with significant participation from various stakeholders in the industry [1][2] Group 2: Key Themes and Discussions - The conference theme was "Leading Innovation Change, Insight into Transformation Pathways," focusing on the commercialization of innovative drugs and the dual circulation of internal and external markets [2] - The global pharmaceutical market is projected to reach $19 trillion by 2027, with oncology, autoimmune, and metabolic fields being the main growth drivers [2][3] - Challenges for companies going global include geopolitical issues, registration barriers, and commercialization difficulties, necessitating capabilities in market insight, efficient registration, channel coverage, academic support, and risk management [3] Group 3: Collaborative Efforts and Future Directions - The conference emphasized the need for collaboration among industry, academia, research, medicine, and investment sectors to build a globally competitive biopharmaceutical innovation ecosystem [2] - The discussions highlighted that the Chinese biopharmaceutical industry is at a critical stage of transitioning from "local innovation" to "global value," requiring technological innovation, capital support, policy backing, and international cooperation [3]